These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 23674882)

  • 1. Therapeutic efficacy of the Qing Dai in patients with intractable ulcerative colitis.
    Suzuki H; Kaneko T; Mizokami Y; Narasaka T; Endo S; Matsui H; Yanaka A; Hirayama A; Hyodo I
    World J Gastroenterol; 2013 May; 19(17):2718-22. PubMed ID: 23674882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Efficacy and Safety of Oral Qing-Dai in Patients with Ulcerative Colitis: A Single-Center Open-Label Prospective Study.
    Sugimoto S; Naganuma M; Kiyohara H; Arai M; Ono K; Mori K; Saigusa K; Nanki K; Takeshita K; Takeshita T; Mutaguchi M; Mizuno S; Bessho R; Nakazato Y; Hisamatsu T; Inoue N; Ogata H; Iwao Y; Kanai T
    Digestion; 2016; 93(3):193-201. PubMed ID: 26959688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Qing-Dai for pediatric ulcerative colitis multicenter survey and systematic review.
    Kudo T; Jimbo K; Shimizu H; Iwama I; Ishige T; Mizuochi T; Arai K; Kumagai H; Uchida K; Abukawa D; Shimizu T
    Pediatr Int; 2022 Jan; 64(1):e15113. PubMed ID: 35831249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of Fufangkushen colon-coated capsule in the treatment of ulcerative colitis compared with mesalazine: a double-blinded and randomized study.
    Gong Y; Zha Q; Li L; Liu Y; Yang B; Liu L; Lu A; Lin Y; Jiang M
    J Ethnopharmacol; 2012 Jun; 141(2):592-8. PubMed ID: 21911045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colitis with wall thickening and edematous changes during oral administration of the powdered form of Qing-dai in patients with ulcerative colitis: a report of two cases.
    Kondo S; Araki T; Okita Y; Yamamoto A; Hamada Y; Katsurahara M; Horiki N; Nakamura M; Shimoyama T; Yamamoto T; Takei Y; Kusunoki M
    Clin J Gastroenterol; 2018 Aug; 11(4):268-272. PubMed ID: 29549501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Indigo Naturalis Therapy for Ulcerative Colitis: A Case Series.
    Urushikubo J; Yanai S; Nakamura S; Kawasaki K; Akasaka R; Sato K; Toya Y; Asakura K; Gonai T; Matsumoto T
    Intern Med; 2019 Aug; 58(16):2299-2304. PubMed ID: 31118381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of Pulmonary Arterial Hypertension in a Patient Treated with Qing-Dai (Chinese Herbal Medicine).
    Misumi K; Ogo T; Ueda J; Tsuji A; Fukui S; Konagai N; Asano R; Yasuda S
    Intern Med; 2019 Feb; 58(3):395-399. PubMed ID: 30210129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Indigo Naturalis in a Multicenter Randomized Controlled Trial of Patients With Ulcerative Colitis.
    Naganuma M; Sugimoto S; Mitsuyama K; Kobayashi T; Yoshimura N; Ohi H; Tanaka S; Andoh A; Ohmiya N; Saigusa K; Yamamoto T; Morohoshi Y; Ichikawa H; Matsuoka K; Hisamatsu T; Watanabe K; Mizuno S; Suda W; Hattori M; Fukuda S; Hirayama A; Abe T; Watanabe M; Hibi T; Suzuki Y; Kanai T;
    Gastroenterology; 2018 Mar; 154(4):935-947. PubMed ID: 29174928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dramatically Improved Severe Pulmonary Arterial Hypertension Caused by Qing-Dai (Chinese Herbal Drug) for Ulcerative Colitis.
    Kubota K; Imai Y; Okuyama T; Ishiyama Y; Ueno S; Kario K
    Int Heart J; 2023; 64(2):316-320. PubMed ID: 37005323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chinese herbal extract granules combined with 5-aminosalicylic acid for patients with moderately active ulcerative colitis: study protocol for a multicenter randomized double-blind placebo-controlled trial.
    Shen Z; Zheng K; Zou J; Gu P; Xing J; Zhang L; Zhu L; Shen H
    Trials; 2021 Jan; 22(1):55. PubMed ID: 33441157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of an Indigo Naturalis Suppository for Topical Induction Therapy in Patients with Ulcerative Colitis.
    Yoshimatsu Y; Naganuma M; Sugimoto S; Tanemoto S; Umeda S; Fukuda T; Nomura E; Yoshida K; Ono K; Mutaguchi M; Nanki K; Mizuno S; Mikami Y; Fukuhara K; Sujino T; Takabayashi K; Ogata H; Iwao Y; Kanai T
    Digestion; 2020; 101(4):492-498. PubMed ID: 31238326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of children and adolescents with ulcerative colitis by adsorptive depletion of myeloid lineage leucocytes as monotherapy or in combination with low dose prednisolone after failure of first-line medications.
    Tanaka T; Sugiyama S; Goishi H; Kajihara T; Akagi M; Miura T
    BMC Gastroenterol; 2013 Aug; 13():130. PubMed ID: 23961883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent trends and future directions for the medical treatment of ulcerative colitis.
    Naganuma M; Mizuno S; Nanki K; Sugimoto S; Kanai T
    Clin J Gastroenterol; 2016 Dec; 9(6):329-336. PubMed ID: 27699641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus.
    Bressler B; Marshall JK; Bernstein CN; Bitton A; Jones J; Leontiadis GI; Panaccione R; Steinhart AH; Tse F; Feagan B;
    Gastroenterology; 2015 May; 148(5):1035-1058.e3. PubMed ID: 25747596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Qing Dai attenuates nonsteroidal anti-inflammatory drug-induced mitochondrial reactive oxygen species in gastrointestinal epithelial cells.
    Saito R; Tamura M; Matsui H; Nagano Y; Suzuki H; Kaneko T; Mizokami Y; Hyodo I
    J Clin Biochem Nutr; 2015 Jan; 56(1):8-14. PubMed ID: 25678747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of pulmonary arterial hypertension following long-term Qing-Dai use for ulcerative colitis.
    Inoue Y; Ishihara A; Mori T; Horio S; Yoshizane T; Arai M; Noda T
    J Cardiol Cases; 2023 May; 27(5):218-221. PubMed ID: 37180221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Oral Qing-Dai Medication on Pulmonary Arterial Pressure Levels in Patients With Ulcerative Colitis.
    Orihara Y; Asakura M; Hida N; Kawai M; Sato T; Nishimura K; Masai K; Matsumoto Y; Okuhara Y; Goda A; Masuyama T; Nakamura S; Ishihara M
    Circ J; 2020 Jul; 84(8):1339-1345. PubMed ID: 32595175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors affecting short- and long-term effects of leukocyte removal therapy in active ulcerative colitis.
    Nakano R; Iwakiri R; Ikeda Y; Kishi T; Tsuruoka N; Shimoda R; Sakata Y; Yamaguchi K; Fujimoto K
    J Gastroenterol Hepatol; 2013 Feb; 28(2):303-8. PubMed ID: 23339387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study.
    Bosca-Watts MM; Cortes X; Iborra M; Huguet JM; Sempere L; Garcia G; Gil R; Garcia M; Muñoz M; Almela P; Maroto N; Paredes JM
    World J Gastroenterol; 2016 Dec; 22(47):10432-10439. PubMed ID: 28058024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Maintenance Effect of Qing Dai for Ulcerative Colitis.
    Suzuki H; Mizokami Y; Gosho M; Kaneko T; Matsui H; Yanaka A
    J Altern Complement Med; 2018 Nov; 24(11):1130-1131. PubMed ID: 29664682
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.